Astymin-SN Infusion

Introduction

Astymin-SN is a prescription medication that contains the active ingredients L-Leucine and L-Isoleucine. It is available in the form of an infusion and is used for a variety of medical conditions.

Uses

Astymin-SN is primarily prescribed to support the nutritional needs of patients who are unable to consume an adequate diet orally. It is often used in situations where oral intake is not possible or insufficient, such as during recovery from surgery or illness.

Dosage and Administration

The dosage and administration of Astymin-SN should be determined by a healthcare professional, taking into account the individual’s specific nutritional needs and medical condition. It is typically administered intravenously and the infusion rate may vary depending on the patient’s requirements. Follow the instructions provided by your healthcare provider and not exceed the recommended dosage.

Mechanism of Action

Astymin-SN contains L-Leucine and L-Isoleucine, which are essential amino acids. These amino acids play a crucial role in protein synthesis and are involved in various metabolic processes in the body. By providing these essential nutrients, Astymin-SN helps support the body’s nutritional needs during times when oral intake is not possible or insufficient.

Side Effects

Common side effects may include gastrointestinal discomfort, such as nausea or diarrhea. Discuss any persistent or bothersome side effects with your healthcare provider.

Serious side effects are rare but may include allergic reactions or signs of infection at the injection site. If you experience any unusual or severe side effects, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter drugs, and any dietary supplements. Certain medications may interact with Astymin-SN, potentially affecting its effectiveness or increasing the risk of side effects. Your healthcare provider will consider these potential interactions when prescribing Astymin-SN.

Precautions

Before using Astymin-SN, inform your healthcare provider about any known allergies or sensitivities to the active ingredients or any other medications. Additionally, discuss your medical history, including any pre-existing medical conditions or ongoing treatments.

Astymin-SN is contraindicated in individuals with known hypersensitivity to the active ingredients or any of the components of the infusion. It should not be used in patients with certain metabolic disorders, such as maple syrup urine disease.

Storage

Astymin-SN should be stored in a cool, dry place away from direct sunlight. It should be kept out of the reach of children and pets. Follow the specific storage instructions provided by your healthcare provider or the product packaging.

Patient Tips

• Follow the instructions provided by your healthcare provider regarding the dosage and administration of Astymin-SN.
• If you have any questions or concerns about the medication or its usage, do not hesitate to reach out to your healthcare provider.
• Keep track of any side effects you experience and inform your healthcare provider.
• Do not exceed the recommended dosage or change the infusion rate without consulting your healthcare provider.
• Store the medication as instructed and check the expiration date before use.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Low blood sugar (hypoglycaemia) (NHS UK) [Accessed 16 Jun. 2024] (online) Available at:
• Primene: Package Insert Prescribing Information (Drugs.com) [Accessed 21 Jun. 2024] (online) Available at:
• Beta-ketothiolase deficiency (MedlinePlus) [Accessed 8 Jun. 2024] (online) Available at:
• Wang X. Strategy for improving L-isoleucine production efficiency in Corynebacterium glutamicum. Appl Microbiol Biotechnol. 2019 Mar;103(5):2101-2111. doi: 10.1007/s00253-019-09632-2. Epub 2019 Jan 20. [Accessed 19 Jun. 2024] Available at: